An FDA investigation announced in late January is exploring the cardiovascular risks of drugs such as AndroGel, Testim, Fortesta and Axiron. The FDA announced that it would be investigating the risk of stroke, heart attack and death in men who are taking these drugs by prescription.
Reportedly, more than 5.5 million men filled prescriptions for drugs meant to treat the symptoms of low testosterone, a condition coined by big pharma as Low-T. The testosterone replacement industry grew about 500 percent over the past decade. However, the FDA explained, two recent studies suggested an increase in cardiovascular events in certain groups of men and prompted the investigation.
Studies include one from the National Institutes of Health and UCLA revealing that men over 65 have nearly double the risk of a heart attack after taking testosterone therapy, as do those under 65 with a history of heart disease. An additional study revealed similar results. Disregarding these studies, and the slew of cardiovascular adverse events being reported for prescription testosterone, the labels remain silent as to these risks.
The FDA encouraged health care providers to consider whether the benefits of the drugs exceeded the potential risks from their use. Public Citizen has since filed a Citizen’s Petition requesting that a black box label warning of cardiovascular risks be placed on prescription testosterone package inserts.
The Levensten Law Firm is one of the first firms in the nation to focus investigating claims against AbbVie, the maker of AndroGel. We are compiling evidence to be used in lawsuits against abbey for its failure to warn patients and health care providers about the risks associated with this medication. If you or a loved one has suffered a cardiovascular event after using a prescription testosterone therapy drug, contact us today for a free consultation though this site, or the firm’s website www.levenstenlawfirm.com.